.png)
A new pathway to precision: anatomical, airway-based ablation for peripheral NSCLC.
Ardens Lifescience is developing a novel bronchoscopic ablation system (CAROL) for peripheral non-small cell lung cancer (NSCLC). The device employs a breakthrough, anatomy-conforming design that surrounds the tumor to ensure complete and uniform ablation from within the airway. This approach enables precise, tissue-sparing therapy beyond the reach of conventional percutaneous or surgical ablation. The first-in-human study begins soon.
Research
In a porcine model, the linked study (below) demonstrates a conforming electrode technique via bronchial tree conversion using liquid metal (CAROL) that anatomically surrounds the lung nodule, enabling consistent and effective ablation—overcoming limitations of rigid, percutaneous electrodes.
Shah, I. A., et al. (2023). Conversion of the bronchial tree into a conforming electrode to ablate the lung nodule in a porcine model. Communications Medicine, 3, Article 129. https://doi.org/10.1038/s43856-023-00362-1
Clinical Progress
The first-in-human (FIH) study of CAROL has been approved and will be led by Professor Daniel Steinfort in Australia. The protocol is sponsored and overseen by a distinguished pulmonary interventionalist at the University of Melbourne / Royal Melbourne Hospital.
Investigational device. Not for sale.
Availability subject to applicable laws and regulations.
© 2025 Ardens Lifesciences Inc.